Protagonist Therapeutics Return on Investment 2015-2022 | PTGX
Current and historical return on investment (ROI) values for Protagonist Therapeutics (PTGX) over the last 10 years.
| Protagonist Therapeutics ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2022-03-31 |
$-0.12B |
|
inf% |
| 2021-12-31 |
$-0.13B |
|
inf% |
| 2021-09-30 |
$-0.11B |
|
inf% |
| 2021-06-30 |
$-0.08B |
|
inf% |
| 2021-03-31 |
$-0.07B |
|
inf% |
| 2020-12-31 |
$-0.07B |
|
-361.11% |
| 2020-09-30 |
$-0.06B |
|
-155.56% |
| 2020-06-30 |
$-0.07B |
|
-177.78% |
| 2020-03-31 |
$-0.09B |
$0.07B |
-209.88% |
| 2019-12-31 |
$-0.08B |
$0.09B |
-355.56% |
| 2019-09-30 |
$-0.08B |
|
inf% |
| 2019-06-30 |
$-0.07B |
|
inf% |
| 2019-03-31 |
$-0.05B |
|
inf% |
| 2018-12-31 |
$-0.04B |
|
inf% |
| 2018-09-30 |
$-0.03B |
|
inf% |
| 2018-06-30 |
$-0.03B |
|
inf% |
| 2018-03-31 |
$-0.03B |
|
inf% |
| 2017-12-31 |
$-0.04B |
|
inf% |
| 2017-09-30 |
$-0.05B |
|
inf% |
| 2017-06-30 |
$-0.05B |
|
inf% |
| 2017-03-31 |
$-0.04B |
|
inf% |
| 2016-12-31 |
$-0.03B |
|
inf% |
| 2016-06-30 |
$-0.02B |
|
inf% |
| 2016-03-31 |
$-0.01B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.385B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
